This is a working overview of triagonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-04 and is reviewed periodically as new material appears.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Haas solved for the Planck constant using the then-current value for the radius of the hydrogen atom. Three years later, Bohr would use similar equations with different interpretation. Bohr took the Planck constant as given value and used the equations to predict, a, the radius of the electron orbiting in the ground state of the hydrogen atom. This value is now called the Bohr radius.
=== Other uses in performing arts === "Access all areas", a form of backstage pass Association of Amateur Artists, a theatre association in Peru Asia Artist Awards, the South Korean annual award ceremony hosted by Star News 98.9 FM (Brisbane), also known as Triple A Murri Country, an Australian community radio station
Pascal's law (also Pascal's principle or the principle of transmission of fluid-pressure) is a principle in fluid mechanics that states that a pressure change at any point in a confined incompressible fluid is transmitted throughout the fluid such that the same change occurs everywhere. The law was established by French mathematician Blaise Pascal in 1653 and published in 1663.
Sources: en.wikipedia.org
== Honours == Du Vigneaud joined Alpha Chi Sigma while at the University of Illinois in 1930. He was elected to the United States National Academy of Sciences and the American Philosophical Society in 1944, and the American Academy of Arts and Sciences in 1948. He received the 1955 Nobel Prize in Chemistry "for his work on biochemically important sulphur compounds, especially for the first synthesis of a polypeptide hormone," a reference to his work on the peptide hormone oxytocin.
"Polish" heroin (also kompot and compote in drug culture slang) is a crude preparation of heroin made from poppy straw. It is an opioid, used recreationally as a psychoactive drug. Poppy straw, like opium, is harvested from the opium poppy (Papaver somniferum). Polish heroin was used mainly in Central and Eastern Europe prior to the dissolution of the Soviet Union and the end of communist control of the countries of the Warsaw Pact or Eastern Bloc. While related to opium, Polish heroin more nearly resembles poppy tea in its impurity, but can be very potent. This drug was also considered by Eastern Bloc addicts to be one of last resort when refined heroin, morphine, or other similar drugs were unavailable, as was often the case during the 1950s through the end of the Soviet era. Illicit drug trafficking and clandestine drug manufacture within the communist-governed nations of Poland, Hungary, Romania, Bulgaria, Russia itself, and others was on a much smaller scale and the supply far more erratic and unreliable compared to that of Western nations. Opium poppies, by contrast, were widely available and relatively inexpensive. The drug has been known as early as the 1940s. The drug in its finished state is a bitter brown fluid looking like tea or cola in color. Polish heroin contains diacetylmorphine (heroin), 6-monoacetylmorphine (active metabolite of heroin), 3-monoacetylmorphine (less-active metabolite of heroin), morphine and small amounts of codeine.
Later that month, during the final days before the United States fell off the "fiscal cliff", Biden's relationship with McConnell again proved important as the two negotiated a deal that led to the American Taxpayer Relief Act of 2012 being passed at the start of 2013.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.